MLTX – moonlake immunotherapeutics - class a ordinary shares (US:NASDAQ)
Stock Stats
News
MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "mixed" rating to a "sell" rating.
MoonLake Immunotherapeutics (NASDAQ:MLTX) was given a new $24.00 price target on by analysts at UBS Group AG.
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock, up previously from $26.00.
MoonLake Immunotherapeutics (NASDAQ:MLTX) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating.
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Form 4 MoonLake Immunotherapeut For: Jan 07 Filed by: Reich Kristian
Form 4 MoonLake Immunotherapeut For: Jan 07 Filed by: Bodenstedt Matthias
Form 4 MoonLake Immunotherapeut For: Jan 07 Filed by: Santos da Silva Jorge
Form 8-K MoonLake Immunotherapeut For: Jan 08
Form 4 MoonLake Immunotherapeut For: Dec 19 Filed by: Reich Kristian
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.